Seasoned Industry Expert Joins Deep Bio to Drive Commercial Growth and Expansion. Deep Bio appoints Grant Carlson as the company’s Chief Commercial Officer.
SEOUL, South Korea, July 30, 2023 /PRNewswire-PRWeb/ — Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the appointment of Grant Carlson as its new Chief Commercial Officer (CCO). With over 30 years of experience in molecular diagnostics, biotechnology and life sciences industries, Carlson brings a wealth of knowledge to Deep Bio.
In his new role, Carlson will be responsible for overseeing Deep Bio’s commercial strategy, driving business development, and expanding the company’s market presence globally. He will leverage his deep understanding of the pathology market and proven track record of driving exponential sales growth to further strengthen Deep Bio’s outreach and customer base.
Prior to joining Deep Bio, Carlson held several executive roles in leading healthcare and biopharma companies. Notably, he served as the Chief Commercial Officer at PathAI Diagnostics, where he played a pivotal role in spearheading US sales and initiating commercial sales for remote workstations in the US, delivering significant growth.
Carlson also held key leadership positions at NeoGenomics Laboratories and Dianon Systems, where he demonstrated his ability to drive rapid organizational growth in emerging markets through strategic partnerships and implementation of effective commercialization strategies.
“We are thrilled to welcome Grant to the Deep Bio team,” said Sun Woo Kim, CEO and founder of Deep Bio. “His unparalleled experience and excellent track record in business development and commercial operations will be instrumental in accelerating growth. Grant’s deep understanding of the anatomic, clinical and digital pathology markets will play a crucial role in expanding our reach. Grant’s appointment marks a significant milestone in Deep Bio’s vision of transforming cancer diagnosis through our AI diagnostic solutions.”
“I am honored and excited to join the Deep Bio team at this pivotal moment,” Carlson said. “I am thrilled to be part of a company that is revolutionizing cancer diagnosis and treatment worldwide by applying groundbreaking AI technologies to pathology diagnostics. The opportunity to make a profound impact on the lives of cancer patients is truly inspiring. I look forward to collaborating closely with the incredibly talented team at Deep Bio, working together to accelerate our market presence and drive innovation.”
Carlson joins Deep Bio’s team, alongside a distinguished advisory board comprising industry leaders such as Michael Bonham, MD, PhD, the former Chief Medical Officer (CMO) of Proscia, and Kamala Maddali, DVM, PhD, the founder and CEO of Health Collaborations, an AI-based precision medicine consulting firm.
Dr. Bonham is a respected board-certified anatomic pathologist who has garnered much recognition for his leadership pioneering developments in digital pathology. Prior to joining Deep Bio, his previous roles include Chief Medical Officer at Proscia, Head of Pathology at Driver, and Clinical Director of Pathology at Genomic Health. Throughout his career, Dr. Bonham has demonstrated expertise in the development and implementation of digital pathology software, genomic test development, and strategic clinical partnerships.
Dr. Kamala Maddali, the founder and CEO of Health Collaborations, brings over 17 years of experience in precision medicine and clinical trials in oncology. She has held key leadership roles and served as a commercial executive for many Fortune 500 companies, including Quest Diagnostics, Merck, and Quintiles, where she fostered strategic partnerships and relationships with key opinion leaders.
“As the global digital pathology market continues to grow, Deep Bio is actively exploring opportunities for international expansion and market penetration,” said Kim. “Grant’s expertise across the diagnostics and healthcare industries will be integral to accelerating commercial growth and innovative product development at Deep Bio.”
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr
Media Contact
Jenny, Deep Bio Inc., 82 70-7703-4746, [email protected], www.deepbio.co.kr
SOURCE Deep Bio Inc.
